Studies

Klinische Studien am IDF
StudyInclusion criteriaStudy goalContactInformation

Freder1k study

 

 

 

  • newborns and babies until the age of 7 days in Bavaria, Lower Saxony, Saxony and Thuringia
Free early detection of an increased type 1 diabetes risk immediately after birth as part of the newborn screening or during a subsequent visit to the pediatrician up to the age of 7 days. The type 1 diabetes risk genes are determined based on a few drops of blood. If there is an increased risk of type 1 diabetes, participation in type 1 diabetes prevention studies is offered (including the POInT study, see below).

Dr. Christiane Winkler

tel.: 0800-000 00 18
(free)

 

Website

SINT1A study

  • children up to the age of 6 weeks
  • with genetic risk for type 1 diabetes
The SINT1A study (Supplementation with B. infantis for Mitigation of Type 1 Diabetes Autoimmunity) aims to prevent the development of islet autoimmunity and type 1 diabetes. The daily administration of a natural probiotic is intended to promote the development of intestinal flora in infants in order to regulate the child's immune system.

Univ.-Prof. Dr. med. Anette-Gabriele Ziegler

PD Dr. med. Peter Achenbach

tel.: 0800-000 00 18 (free)

Website

POInT trial

 

 

  • children between 4 and 7 months
  • with genetic risk for type 1 diabetes
  • after introduction of foodstuffs
The POInT (Primary Oral Insulin Trial) trial aims to prevent the development of islet autoimmunity and the development of type 1 diabetes. The daily intake of insulin powder with food intends to train and sensitize the immune system at an early stage so that defective autoimmunity does not occur.

Univ.-Prof. Dr. med. Anette-Gabriele Ziegler

PD Dr. med. Peter Achenbach

tel.: 0800-000 00 18 (free)

 

Website

Fr1daplus study

 

  • all Bavarian children from 2 to 10 years of age
The Fr1daplus study "Type 1 diabetes: early detection - early treatment" detects an early stage of type 1 diabetes. Early diagnosis means that it is possible to treat type 1 diabetes from the outset and to avoid metabolic disorders. It is possible to participate in the prevention study Fr1da Insulin Intervention. The study aims to delay or stop the progression of the disease (see below).

Univ.-Prof. Dr. med. Anette-Gabriele Ziegler

tel.: 0800–4648835 (free)

 

Website (German)

Fr1da Insulin Intervention trial

 

  • children between 2 and 12 years
  • with at least 2 islet autoantibodies (pre-type 1 diabetes)
  • with normal blood values in OGTT
  • living in Germany
Study participants - children with an early stage of type 1 diabetes - receive oral insulin powder to prevent the development of type 1 diabetes by immune sensitization. The insulin does not lower blood sugar levels, but is intended to have a positive effect on the immune system, similar to a protective vaccination.

Univ.-Prof. Dr. med. Anette-Gabriele Ziegler

tel.: 0800–4648835 (free)

 

Website (German)

Early detection of type 1 diabetes for relatives

 

  • children and young adults between 1 and 21 years living in Germany
  • at least one parent, child, (half) sister, (half) brother, aunt, uncle, cousin, niece or nephew has type 1 diabetes
  • no previous diagnosis of type 1 diabetes
Close relatives of people with type 1 diabetes have an increased risk of developing type 1 diabetes. For this reason, we offer them a free test to detect an early stage of the disease. Participation is possible in all of Germany.

Univ.-Prof. Dr. med. Anette-Gabriele Ziegler

tel.: 0800–4648835 (free)

 

Website (German)